Background: Patients at elevated risk of drug-resistant tuberculosis (TB) are prioritized for Xpert(®) MTB/RIF testing; however, the clinical usefulness of the test in this population is understudied.
Design: From November 2011 to June 2014, consecutive out-patients with a history of previous TB in high-density suburbs of Harare, Zimbabwe, were tested using Xpert, solid and liquid culture, and the microscopic observation drug susceptibility assay. Diagnostic accuracy for rifampin (RMP) resistance and time to initiation of second-line regimens were ascertained. The rpoB gene was sequenced in cases with culture-confirmed RMP resistance and genotypic susceptibility.
Results: Among 352 retreatment patients, 71 (20%) were RMP-resistant, 98 (28%) RMP-susceptible, 64 (18%) culture-negative/Xpert-positive, and 119 (34%) culture-negative/Xpert-negative. Xpert had a sensitivity of 86% (95%CI 75-93) and a specificity of 98% (95%CI 92-100) for RMP-resistant TB. The positive predictive value of Xpert-determined RMP resistance for multidrug-resistant TB (MDR-TB) was 82% (95%CI 70-91). Of 71 (83%) participants, 59 initiated treatment with second-line drugs, with a median time to treatment initiation of 18 days (IQR 10-44).
Conclusion: The diagnostic accuracy of Xpert for RMP resistance is high, although the predictive value for MDR-TB was lower than anticipated. Xpert allows for faster initiation of second-line treatment than culture-based drug susceptibility testing under programmatic conditions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961684 | PMC |
| http://dx.doi.org/10.5588/ijtld.15.0696 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of rest interval following a series of tuck jumps on anaerobic performance.
J Exerc Sci Fit
January 2025
Department of Health, Sport, and Exercise Sciences, University of Kansas Edwards Campus, Overland Park, KS, USA.
Background/objective: This study assessed the influence of rest interval duration after tuck jumps on 10-s Wingate outcomes and countermovement jump height.
Methods: Eighteen resistance trained individuals (males: n = 10, 21.3 ± 3.
Molecular Characterization of Multidrug-Resistant and Hypervirulent New Delhi Metallo-Beta-Lactamase in Lazio, Italy: A Five-Year Retrospective Study.
Antibiotics (Basel)
November 2024
National Institute for Infectious Diseases "L. Spallanzani" Istituto di Ricovero e Cura a Carattere Scientifico, via Portuense 292, 00149 Rome, Italy.
Background/objectives: Antimicrobial resistance represents a challenge to public health systems because of the array of resistance and virulence mechanisms that lead to treatment failure and increased mortality rates. Although for years the main driver of carbapenem resistance in Italy has been the KPC carbapenemase, recent years have seen an increase in VIM and NDM metallo-beta-lactamases (MBLs). We conducted a five-year survey of New Delhi Metallo-beta-Lactamase (NDM)-producing (NDM-Kpn) clinical isolates from the Lazio region, Italy; the study aimed to elucidate the molecular mechanisms underpinning their resistant and virulent phenotype.
View Article and Find Full Text PDFOral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer.
BMC Cancer
June 2024
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Article Synopsis
- Tumor hypoxia, which is when there isn't enough oxygen in parts of tumors, makes prostate cancer harder to treat and can lead to worse outcomes for patients.
- A study tested a special drug called Pimonidazole (PIMO) in 39 prostate cancer patients to see how it can help in understanding tumor hypoxia and its effects on cancer.
- The researchers discovered different patterns of PIMO staining in tumors, and one pattern was linked to more dangerous cancer traits, helping to create a new DNA signature that can identify patients at higher risk for serious disease.
Background: This study aims to compare the performance of line probe assay (LPA) on smear-negative samples with that of smear-positive samples for diagnosing pulmonary tuberculosis (PTB) and first-line drug sensitivity testing (FL DST).
Methods: A total of 196 sputum samples including both smear-positive (112) and negative (84) samples of patients suspected of PTB were subjected to LPA for TB detection and FL DST. TB culture followed by MPT 64 Ag was done and conventional FL DST was performed on all culture-positive isolates.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Lancet HIV
June 2024
Merck & Co, Rahway, NJ, USA. Electronic address:
Background: Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for resistance. We investigated a switch from bictegravir, emtricitabine, and tenofovir alafenamide to doravirine (100 mg) and islatravir (0·75 mg) in virologically suppressed adults with HIV-1.
Methods: We conducted a phase 3, multicentre, randomised, active-controlled, double-blind, double-dummy, non-inferiority trial at 89 research, community, and hospital-based clinics in 11 countries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!